Clinical Trial Update: A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of trastuzumab with bevacizumab and sequential capecitabine or docetaxel in HER2-positive locally recurrent or metastatic breast cancer has been w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• HERCEPTIN (trastuzumab)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN